Skin gadolinium following use of MR contrast agents in a rat model of nephrogenic systemic fibrosis

Radiology

Volumn 263, Issue 1, 2012, Pages 107-116

  Haylor, John ^a   Schroeder, Josef ^b   Wagner, Bart ^c   Nutter, Faith ^a   Jestin, Gaëlle ^d   Idée, Jean Marc ^d   Morcos, Sameh ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c NORTHERN GENERAL HOSPITAL   (United Kingdom)

^d Research Division   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BLOOD CLOTTING FACTOR 8A; CALVASCULIN; CD34 ANTIGEN; COLLAGEN FIBRIL; CREATININE; EOSIN; GADODIAMIDE; GADOTERATE MEGLUMINE; HEMATOXYLIN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; CONTRAST MEDIUM; GADOLINIUM PENTETATE; MEGLUMINE; ORGANOMETALLIC COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; COLLAGEN BUNDLE DENSITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CUTANEOUS PARAMETERS; DERMAL THICKNESS; DOSE KIDNEY FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG RETENTION; DRUG STABILITY; DRUG TISSUE LEVEL; ENERGY FILTERED TRANSMISSION ELECTRON MICROSCOPY; EXTRACELLULAR MATRIX; HISTOLOGY; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; MORPHOMETRICS; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN CELL; SKIN EXAMINATION; SKIN FIBROBLAST; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; ATOMIC ABSORPTION SPECTROMETRY; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; ENZYME IMMUNOASSAY; METABOLISM; SKIN; WISTAR RAT;

ANIMALS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; GADOLINIUM DTPA; IMMUNOENZYME TECHNIQUES; MALE; MEGLUMINE; MICROSCOPY, ELECTRON, TRANSMISSION; NEPHROGENIC FIBROSING DERMOPATHY; ORGANOMETALLIC COMPOUNDS; RATS; RATS, WISTAR; SKIN; SPECTROPHOTOMETRY, ATOMIC;

EID: 84861321975     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12110881     Document Type: Article

References (38)

1. Cowper SE. Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium. Adv Dermatol 2007;23:131-154.
2. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007;22(11):3174-3178. (Pubitemid 350202540)
3. Grobner T. Gadolinium: specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21(4):1104-1108.
4. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007;188(2):586-592. (Pubitemid 46167763)
5. Port M, Idée JM, Medina C, Robic C, Sabatou M, Corot C. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals 2008;21(4):469-490.
6. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 2007;80(950):73-76. (Pubitemid 46951248)
7. Perazella MA. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm. Curr Opin Nephrol Hypertens 2009;18(6):519-525.
8. Morcos SK. Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis: what did we learn so far? Eur Radiol 2011;21(3):496-500.
9. Fretellier N, Idée JM, Guerret S, et al. Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest Radiol 2011;46(2):85-93.
10. Sieber MA, Lengsfeld P, Frenzel T, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 2008;18(10):2164-2173.
11. Haylor J, Dencausse A, Vickers M, et al. Nephrogenic gadolinium biodistribution and skin cellularity following a single injection of Omniscan in the rat. Invest Radiol 2010;45(9):507-512.
12. Pietsch H, Lengsfeld P, Jost G, Frenzel T, Hütter J, Sieber MA. Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents. Eur Radiol 2009;19(6):1417-1424.
13. Haylor J, Vickers ME, Morcos SK. Interference of gadolinium-based contrast agents with the measurement of serum creatinine by the Jaffe reaction. Br J Radiol 2009;82(977):438-439.
14. Frame EM, Uzgiris EE. Gadolinium determination in tissue samples by inductively coupled plasma mass spectrometry and inductively coupled plasma atomic emission spectrometry in evaluation of the action of magnetic resonance imaging contrast agents. Analyst (Lond) 1998;123(4):675-679.
15. Schroeder JA, Weingart C, Coras B, et al. Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol 2008;3(4):968-975.
16. Wadas TJ, Sherman CD, Miner JH, Duncan JR, Anderson CJ. The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice. Magn Reson Med 2010;64(5):1274-1280.
17. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56(1):27-30. (Pubitemid 44969309)
18. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56(1):21-26. (Pubitemid 46017000)
19. Thakral C, Abraham JL. Automated scanning electron microscopy and x-ray microanalysis for in situ quantification of gadolinium deposits in skin. J Electron Microsc (Tokyo) 2007;56(5):181-187.
20. Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 2008;43(1):65-75.
21. Pietsch H, Lengsfeld P, Steger-Hartmann T, et al. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol 2009;44(4):226-233.
22. Fretellier N, Idée JM, Dencausse A, et al. Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol 2011;46(5):292-300.
23. Canty EG, Kadler KE. Procollagen trafficking, processing and fibrillogenesis. J Cell Sci 2005;118(Pt 7):1341-1353. (Pubitemid 40585115)
24. Voelz H. The "spindle-shaped body" in fibroblasts. J Cell Biol 1964;20:333-337.
25. ten Cate AR. Morphological studies of fibrocytes in connective tissue undergoing rapid remodelling. J Anat 1972;112(Pt 3):401-414.
26. Fernandez-Madrid F, Noonan S, Riddle J. The "spindle-shaped" body in fibroblasts: intracellular collagen fibrils. J Anat 1981;132(Pt 2):157-166. (Pubitemid 11056487)
27. Laurent GJ. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol 1987;252(1 Pt 1):C1-C9.
28. van der Zee E, Everts V, Hoeben K, Beertsen W. Cytokines modulate phagocytosis and intracellular digestion of collagen fibrils by fibroblasts in rabbit periosteal explants: inverse effects on procollagenase production and collagen phagocytosis. J Cell Sci 1995;108(Pt 10):3307-3315.
29. Jiménez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004;50(8):2660-2666. (Pubitemid 39062729)
30. Wermuth PJ, Del Galdo F, Jiménez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 2009;60(5):1508-1518.
31. Signorini M, Bortolotti F, Poltronieri L, Bergamini CM. Human erythrocyte transglutaminase: purification and preliminary characterisation. Biol Chem Hoppe Seyler 1988;369(4):275-281.
32. Johnson TS, Fisher M, Haylor JL, et al. Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease. J Am Soc Nephrol 2007;18(12):3078-3088. (Pubitemid 350223968)
33. Parsons AC, Yosipovitch G, Sheehan DJ, Sangüeza OP, Greenberg CS, Sane DC. Transglutaminases: the missing link in nephrogenic systemic fibrosis. Am J Dermatopathol 2007;29(5):433-436. (Pubitemid 47463850)
34. Drouven BJ, Evans CH. Collagen fibrillogenesis in the presence of lanthanides. J Biol Chem 1986;261(25):11792-11797. (Pubitemid 17206106)
35. Evans CH, Drouven BJ. The promotion of collagen polymerization by lanthanide and calcium ions. Biochem J 1983;213(3):751-758.
36. Kelly BC, Markle LS, Vickers JL, Petitt MS, Raimer SS, McNeese C. The imbalanced expression of matrix metalloproteinases in nephrogenic systemic fibrosis. J Am Acad Dermatol 2010;63(3):483-489.
37. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 1995;30(6):372-380.
38. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM078932.pdf. Published July 6, 2005. Accessed October 2011.